Skip to main
WVE

WVE Stock Forecast & Price Target

WVE Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 54%
Buy 46%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

WAVE Life Sciences is a clinical-stage biotechnology company with a promising RNA medicines platform that has the potential to transform human health by targeting RNA and addressing rare and prevalent disorders. The company's strong toolkit of RNA-targeting modalities gives them a unique advantage in designing and delivering effective treatments. While there are risks to their investment thesis and price target, the company's recent update on the WVE-007 trial data and the potential for Activin pathway inhibition and GLP-1 agonism to result in significant weight loss and preservation of lean muscle mass, suggest a positive outlook for WAVE's future success.

Bears say

WAVE Life Sciences is a biotechnology company with a diverse platform of RNA-targeting modalities. Despite promising preclinical data, the company's current cash position may not be enough to support developmental runway into 2028. Additionally, the market may have overreacted to the company's WVE-007 program, which has a mechanistically nuanced role in adipose tissue and may require further clinical validation to reach its full potential.

WVE has been analyzed by 13 analysts, with a consensus rating of Buy. 54% of analysts recommend a Strong Buy, 46% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Wave Life Sciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Wave Life Sciences (WVE) Forecast

Analysts have given WVE a Buy based on their latest research and market trends.

According to 13 analysts, WVE has a Buy consensus rating as of Jun 17, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $28.92, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $28.92, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Wave Life Sciences (WVE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.